Page last updated: 2024-12-08
terephthalamidine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
terephthalamidine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 159756 |
| CHEMBL ID | 1187958 |
| SCHEMBL ID | 537030 |
| MeSH ID | M0137754 |
Synonyms (18)
| Synonym |
|---|
| 1,4-benzenedicarboximidamide |
| terephthalamidine |
| 15411-54-8 |
| 1,4-diamidinobenzene |
| benzene-1,4-dicarboximidamide |
| AKOS004903531 |
| CHEMBL1187958 |
| SCHEMBL537030 |
| mfcd01108407 |
| DTXSID10165538 |
| terephthalamidin |
| terephthalimidamide |
| FT-0700960 |
| CS-0014259 |
| EN300-817875 |
| benzdiamidine |
| benzene-1,4-dicarboxamidine |
| A937483 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic analysis by HPLC was performed in all patients during their first course." | ( A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion. Campbell, L; Clark, GM; De La Cruz, P; Eckardt, JR; Fields, SM; Hilsenbeck, SG; Kuhn, JG; New, P; Rodriguez, GI; Von Hoff, DD; Weiss, G, 1998) | 0.57 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The limitations of current therapies for the treatment of iron overload or radioisotope contamination have stimulated efforts to develop new orally bioavailable iron and actinide chelators." | ( Multidentate terephthalamidate and hydroxypyridonate ligands: towards new orally active chelators. Abergel, RJ; Raymond, KN, 2011) | 0.37 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.06
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.06) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (9.09%) | 5.53% |
| Reviews | 1 (9.09%) | 6.00% |
| Case Studies | 1 (9.09%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (72.73%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||